SANOFI

Sanofi’s latest IL‑4Rα antibody, oncology antibody‑drug conjugate, and bispecific candidates fuel growth, with strategic partnerships driving innovation and patient access worldwide.

Sanofi’s Q2 2026 results show a 17.8% sales jump, driven by Dupixent and new drugs, and a €2.09 EPS, prompting a 10% upward revenue outlook.

EU probes Sanofi over alleged misleading flu‑vaccine ads, risking up to 10% fine and impacting investor confidence. Learn how the case could reshape pharma marketing.